Sage Journals: Discover world-class research

Abstract

Background/Objective: Senile pruritus (SP) is a prevalent disease that occurs in elderly individuals over the age of 60 and is characterized by the primary symptom of pruritus. The disease's pathogenesis is complex, and clinical practice mainly uses symptomatic treatment drugs. YGZ223 is a traditional Chinese medicine currently in clinical trials for treatment of SP. However, its chemical composition and pharmacological mechanism remain unclear. The purpose of this inquiry is to investigate the workings of YGZ223 in managing SP using network pharmacology, UPLC-MS, and molecular docking. Materials and Method: This investigation employs network pharmacology to anticipate the mode of operation of YGZ223 in alleviating SP, and UPLC-MS is applied to identify the chemical constituents. Molecular docking provides the binding strengths between principal constituents and targets, while animal experiments are performed to validate the antipruritic activity of YGZ223. Results: The compound prescription for SP contains formononetin and erysodienone as effective ingredients. These ingredients have the potential to impact pathways related to cancer, endocrine resistance, and the PI3K/AKT signaling pathway by regulating targets such as AKT1, EGFR, and mTOR. Formononetin and erysodienone have a considerable binding capacity with various targets, the former displaying the strongest binding with AKT1. Animal test results show that the YGZ223 group can significantly reduce the number of tickles in mice compared to the 4-Aminopyridine induced model group, and has a good anti-itch effect. Conclusion: This study demonstrates that YGZ223 has potential anti-SP activity due to multiple constituents, targets, and pathways, and thus lays the groundwork for development of novel therapeutic approaches for SP.

Keywords

network pharmacology molecular docking senile pruritus molecular dynamics simulation UPLC-MS

Introduction

SP can be defined as idiopathic chronic itching in individuals over the age of 60¹ or systemic itching in patients without primary skin lesions.² Pruritus generally originates on the skin, is an unpleasant sensation provoking a desire to scratch and may result in pain, skin damage, and infection.³ Although scratching may generate pleasant sensations, it does not relieve symptoms. On the contrary, it tends to result in damaging cycles of itching and scratching.⁴ Literature reports indicate an SP prevalence of 11% to 78%^5–7 and, as individuals age, immune aging ensues and the incidence rate of pruritus increases.⁸

Due to the unclear pathogenesis of SP, treatment usually involves anti-allergic drugs such as diphenhydramine or loratadine. Corticosteroids and calcineurin inhibitors can also be used to control itching but are accompanied by side effects such as drowsiness and weight gain.⁹ Therefore, the development of innovative treatments for SP is imperative.

YGZ223 is a formula comprised of 7 traditional Chinese medicines including Paeoniae Radix Rubra, Angelicae Sinensis Radix, Cortex Erythrinae, Tribuli Fructus, Sophorae Flavescentis Radix, Dendrobii Caulis, and Zaocys. The formula originates from the clinical experience of the Hubei Provincial Hospital of Traditional Chinese Medicine and has proven therapeutic efficacy against skin pruritus among middle-aged and elderly individuals. This study utilizes network pharmacology methods to uncover the mechanism of YGZ223 in treating SP. UPLC-MS reveals the chemical constituents of YGZ223, molecular docking assesses the bonding ability of the primary constituents to the targets, and the effectiveness of YGZ223 is determined in a 4-aminopyridine-induced mouse itching model.

Materials and Methods

Materials

YGZ223 (batch number 20230417) was obtained from Hubei Provencial Hospital of Traditional Chinese Medicine. Xiaofeng Zhiyang granules (batch number 220107) were obtained from Nanjing Tongrentang Pharmaceutical Co., Ltd. Diphenhydramine hydrochloride tablets (batch numbers 14W10081 and 14W10041) were provided by Yichang Humanwell Pharmaceutical Co., Ltd. Sodium chloride injection (0.9%, batch number 220511522) was purchased from Wuhan Fuxing Biopharmaceutical Co., Ltd. 4-Aminopyridine (4-AP, batch number PWAWH-GU) was provided by Shanghai Tixi Aihua Industrial Development Co., Ltd.

A high-speed freezing centrifuge (Eppendorf AG, 22331 Hamburg), chromatographic system (ACQUITY UPLC M-Class, Waters, USA), and mass spectrometer (Waters Xevo G2-XS, Waters, USA) apparatus were applied.

Animals

SPF grade Kunming mice aged 3 to 4 weeks and weighing 21.67 to 25.70 g were purchased from Hunan Slake Jingda Experimental Animal Co., Ltd, Animal Ethics Number: IACUC (Approved)—YJY-2022-016.

Methods

Chemical Component Acquisition and Target Protein Screening of YGZ223

The chemical composition information of the 7 medicinal herbs of YGZ223 (Paeoniae Radix Rubra, Angelicae Sinensis Radix, Cortex Erythrinae, Tribuli Fructus, Sophorae Flavescentis Radix, Dendrobii Caulis, and Zaocys) was screened using the Herb database,¹⁰ SymMap database,¹¹ the Chemical Professional Database of the Shanghai Institute of Organic Chemistry, and additional literature screening. PubChem¹² was used to identify compounds meeting the 3 SwissADME rules¹³ and conforming with “yes” and “high” requirements for gastrointestinal absorption. Active YGZ223 constituents were retrieved from the SwissTargetPrediction database with a probability >0.1, and target duplication was eliminated.¹⁴

Prediction of SP Targets and Construction of Protein–Protein Interaction Networks

Using the keyword “senile pruritus,” the obtained targets were integrated and de-duplicated with the GeneCards database,¹⁵ DrugBank database,¹⁶ and the TTD database.¹⁷ On the Bioinformatics platform, jvenn¹⁸ was used to create Venn diagrams illustrating the overlap between component targets and disease targets. To obtain preliminary protein–protein interaction networks (PPIs), protein interaction analysis was carried out on the online website STRING,¹⁹ the TSV data file was imported from STRING into Cytoscape,²⁰ and the Centiscape2.2 plugin in Cytoscape and the network analysis option were applied to simplify analysis and plotting.

GO and KEGG Pathway Enrichment Analysis

Genes common to drugs and diseases were imported into the DAVID database²¹ for enrichment analysis of Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG). The GO analysis identified the top 10 significant results with P < .01 while KEGG screened out the top 20 significant pathways. Column charts for the GO analysis and bubble charts for the KEGG analysis were created using the Bioinformatics platform.

Constructing “Herb-Ingredient-Target” and “Components-Targets-Pathways” Networks

Both “herb-ingredient-target” and “constituent-target-pathway” networks were created using Cytoscape software, and analyzed with the Network Analyzer plug-in in Cytoscape, with emphasis on the node degree values and arranging the graphs in order of degrees of freedom.

Preparation of YGZ223 Sample

YGZ223 extract (0.10 g) was accurately measured and transferred into a 10 mL volumetric flask. In a suitable amount of pure water, ultrasound was applied at 53 kHz and 350 W for 30 min. Once cooled down to room temperature, pure water was added to the flask up to the mark. After shaking, a 1 mL sample was placed in a 1.5 mL centrifuge tube. Centrifugation for 10 min at room temperature at 12000 rpm· min⁻¹ was followed by microporous membrane filtration (0.22 μM) to obtain the filtrate.

Chromatography and Mass Spectrometry Conditions

Using a Waters ACQUITY BEH C18 column (1.7 μm, 100 × 2.1 mm) and 0.1% formic acid in water as mobile phase A and acetonitrile as mobile phase B, the following elution procedure was applied: 0 to 8 min, 5% B; 8 to 9 min, 5% to 9% B; 9 to 14 min, 9% B; 14 to 30 min, 9% to 19% B; 30 to 45 min, 19% to 42% B; 45 to 50 min, 42% to 95% B; 50 to 60 min, 95% B; applying flow rate 0.3 mL/min, injection volume 2 μL, detection wavelength 205 nm, and column temperature 30 °C.

Mass spectrometry conditions comprised an ESI ion source, collecting data in both positive and negative ion modes. The MSE mode collects primary and secondary mass spectrometry ions, with a scanning range of m/z 50 to 1500 Da, at electric spray voltage 3000 V, cone hole voltage 20 V, ESI ion source temperature 100 °C, curtain gas 50 L/h, and N2 desolvation gas at a flow rate 1000 L/h.

Data Collection, Statistics, and Chemical Composition Identification

UPLC-MS/MS data was collected and analyzed using a Waters MassLynx V4.1 and MS^E DataViewer 1.2 software. The literature on the chemical constituents and mass spectrometry fragmentation patterns of the 7 medicinal herbs of YGZ223 was reviewed, summarizing the classes of compounds in YGZ223 with reference to the MassBank and PDMB databases, and according to reverse phase chromatography retention times.

Molecular Docking

The 3D structure SDF files of potentially active constituents were downloaded from the PubChem database and were converted into PDB files using OPENBabel software. The complete sequence and high-resolution 3D crystal structures of target proteins were downloaded from RCSB²² and AlphaFold protein database.²³ PyMOL software was used to remove solvent ligands, and hydrogenate the proteins to act as receptors. Small molecule compounds were introduced as ligands to obtain the optimal conformation through conformational binding energy and interaction force analysis. Finally, PyMOL software was used to visualize the molecular docking results.

Molecular Dynamics Simulation of Formononetin-AKT1 complex

Small molecules and proteins were described using GAFF small molecule force field and AMBER-14SB protein force field, respectively. Using the pdb2gmx subroutine to add hydrogen atoms to the system, a truncated cubic TIP3P solvent box was added at a distance of 10 Å in the system,²⁴ and Na⁺/Cl⁻ was added to the system for charge balance. Finally, the topology and parameter files for simulation were output.

Molecular dynamics simulation was conducted using Gromacs 2020.6 softwareff,²⁵ with a simulation duration of 80 ns. Before simulation, the system was optimized for energy by using the mdrun command and the steepest descent method for energy minimization (canonical ensemble), with a starting step size of 0.01 nm and a maximum force tolerance of 1000 kJ/mol • nm. After optimization of the system energy, a 100 ps NVT (isothermal-isochoric) lineage simulation was performed on the system at a fixed volume and constant heating rate, causing the system temperature to slowly rise from 0 K to 310.15 K, further unifying the distribution of solvent molecules in the solvent box. Subsequently, a 100 ps NpT (isothermal-isobaric) ensemble simulation was conducted using a Berendsen constant pressure device to reach pressure equilibrium on the solvent composite system, raising the system pressure to 1 bar. In the MD simulation process, all hydrogen bonds involved are constrained using the LINCS algorithm, with an integration step of 2 fs. The electrostatic interaction was calculated using the Particle mesh Ewald method, with a cutoff value of 1.2 nm. The non-bond interaction truncation value was set to 10 Å and was updated every 10 steps. Periodic elimination was performed on the simulated trajectory and subsequent analysis on RMSD, RMSF, Rg, hydrogen bonding, MM/GBSA, etc. The binding free energy of small molecules and proteins was calculated using the MM/GBSA method.^26–28 This article uses the GB model developed by Nguyen et al for calculation (igb = 2).²⁹

Pharmacodynamic Experiment of YGZ223 on 4-Aminopyridine Induced Skin Itching Model in Mice

Forty SPF grade KM mice, half male and half female, were randomly divided into five groups including the model control group (Model, given physiological saline), the Xiaofeng Zhiyang granule group (XFZY, 10.8 g/kg), the diphenhydramine hydrochloride group (DF, 0.0226 g/kg), the YGZ223 group (19.6 g/kg), and the blank control group (Control, given physiological saline). The YGZ223 group and 2 positive control groups were administered with the corresponding drugs according to body weight every morning. The Model control group and blank Control group were given physiological saline with a dosage volume of 0.2 mL/10 g, and were administered daily for 7 days. After the last 60 min of administration, itching test was conducted: except for the blank control group, mice in other groups were subcutaneously injected with 0.02% 4-AP solution on the back of the tail, 0.1mL per mouse. The blank control group was given an equal amount of physiological saline, 0.1 mL per mouse. Mouse licks itself until it stops counting once (lasting less than 5 s). Longer lasting licking (exceeding 5 s) is recorded as 2 licks during the statistical analysis. The number of licks per mouse is recorded within a 20-min period.

Result

Obtaining Chemical Components and Targets

Through database and literature searches, 253 active constituents were identified in YGZ223. Use of SwissTargetPrediction to screen targets with a probability >0.1 and remove duplicates, 941 targets corresponding to the active constituents in YGZ223 were obtained. The GeneCards database, DrugBank database, and TTD database identified 1077 molecular targets for SP after merging and de-duplication. The common targets of the 2 are 258, which are potential targets for YGZ223 to act on SP, as shown in Figure 1A.

Figure 1.

(A) YGZ223 and Venn map of SP targets. (B) Intersection target PPI network (red indicates a high score, while the larger the circle, the higher the score).

PPI Construction and Core Target Screening

The 258 common targets were uploaded to the STRING database for retrieval of the TSV files which were loaded to Cytoscape, adjusting the visualization parameters Degree >37.39, Closeness >0.002, and Betweenness >263.66, ultimately obtaining 50 nodes and 825 edges (Figure 1B). The top 20 selected key molecular targets are shown in Table 1.

Table 1.

Information on the top 20 key Molecular Targets.

Target	Protein name	Degree	Closeness	Betweenness
AKT1	RAC-alpha serine/threonine-protein kinase	168	0.00289	4432.234
GAPDH	Glyceraldehyde-3-phosphate dehydrogenase	161	0.00283	3770.322
TP53	Cellular tumor antigen p53	138	0.00265	2275.103
VEGFA	Vascular endothelial growth factor A	132	0.00260	1677.309
EGFR	Epidermal growth factor receptor	127	0.00257	1911.761
TNF	Tumor necrosis factor ligand	164	0.00287	5075.667
JUN	Transcription factor	119	0.00253	1110.534
CASP3	Caspase-3	115	0.00251	935.710
MAPK3	MAP kinase-activated protein kinase 3	124	0.00256	1495.404
SRC	Proto-oncogene tyrosine-protein kinase	125	0.00256	2079.847
PTGS2	Prostaglandin G/H synthase 2	102	0.00241	1100.073
STAT3	Signal transducer and activator of transcription 3	118	0.00249	896.190
HIF1A	Hypoxia-inducible factor 1-alpha	103	0.00242	627.179
MTOR	Serine/threonine-protein kinase mTOR	89	0.00233	410.718
HSP90AA1	Heat shock protein HSP 90-alpha	106	0.00244	963.897
TLR4	Toll-like receptor 4	97	0.00237	961.300
MMP9	Matrix metalloproteinase-9	109	0.00244	996.993
PPARG	Peroxisome proliferator-activated receptor γ	95	0.00235	1113.955
ESR1	Ethylene-responsive transcription factor ESR1	106	0.00243	1503.234
CXCL8	Interleukin-8	99	0.00238	718.758

Analysis of YGZ223 Effective Constituents Action Target Network Diagram

The YGZ223 active constituent target network constructed using Cytoscape3.9.1 comprises 429 nodes and 2057 edges. The circle in the graph represents the active constituents, different colors represent different traditional Chinese medicines, and the blue diamond represents 258 common drug disease targets (Figure 2). Cytoscape was used to calculate the degree values of each node, representing the number of correlations between the constituent and the molecular target. The higher the degree value, the greater the likelihood of the constituent's interaction with the disease. Through network analysis, the 10 constituents with the highest degree values were selected. The specific constituents, names, and rankings are shown in Table 2.

Figure 2.

Herb-ingredient-target network. Circles represent herbs and ingredients, while diamonds represent targets. A, B, and C are classification numbers for common constituents of medicinal herbs.

Table 2.

Top 10 Active Constituents in Degree Values.

Component coding	Compound name	Degree values	Origin
C2	Phaseolin	63	Cortex erythrie
C1	Formononetin	51	Radix Sophorae flavescentis
DG33	6-Undecanol	50	Cortex erythrie
DG31	5-Decanone, 2-methyl-	48	Radix Sophorae flavescentis
KS13	Isoxanthohumol	47	Radix Angelicae sinensis
HTP9	Erysodienone	46	Radix Angelicae sinensis
DG32	6-Undecanone	46	Radix Sophorae flavescentis
DG50	Eucalyptin	45	Cortex erythrie
LSSS5	7-Hydroxy-2,3,4,8-tetramethoxyphenanthrene	44	Radix Angelicae sinensis
HTP11	(-)-Vestitol	44	Radix Angelicae sinensis

GO and KEGG Enrichment Analysis of Potential Targets

The GO function obtained after filtering with the DAVID database is shown in Figure 3A. In terms of biological processes, these targets mainly involve response to xenobiotic stimulus, negative regulation of apoptotic processes, response to hypoxia, and inflammatory response. In terms of cell composition, plasma membrane, cell surface, integral component of plasma membrane, and receptor complex are represented. From a functional molecular perspective, these molecular targets mainly participate in functions such as protein serine/threonine/tyrosine kinase activity, protein tyrosine kinase activity, and identical protein binding.

Figure 3.

(A) Bar charts of GO enrichment analysis in the top 10 rankings. (B) Bubble chart analysis of the top 20 pathways of intersection target KEGG.

The first 20 pathways obtained from KEGG enrichment analysis by importing common targets into the DAVID database are plotted as bubble plots in Figure 3B. The target is significantly enriched in multiple pathways such as cancer, lipid and atmospheric clarity, endocrine resistance, PI3K-AKT signaling pathway, fluid shear stress, and atmospheric clarity.

Constituent-Target-Pathway Network Analysis

Based on the 258 common targets and 20 pathways screened through KEGG enrichment, a constituent-target-pathway diagram was constructed using Cytoscape software (Figure 4). The targets were sorted and plotted according to the degree value, and core targets such as GSK3B, PIK3CB, SRC, CSF1R, and FLT1 were selected from the 20 pathways. These may be important targets for YGZ223 to exert therapeutic effects through the first 20 pathways.

Figure 4.

Constituent-target-pathway network. Circles represent constituents, squares represent targets.

UPLC-MS/MS Results

Using MassLynx V4.1 software for peak extraction from raw mass spectrometry data, the mass deviation of the feature peak, element matching, molecular formula prediction, and isotope distribution matching is set within 10 ppm. After extracting the secondary mass spectrometry, the retention time and secondary mass spectrometry information of each compound were analyzed using MassLynx V4.1 software. The chromatographic behavior was compared with relevant references, the MassBank database, and reference materials.

Chemical Composition Analysis of YGZ223

According to the UPLC-MS results, 91 chemical constituents were ultimately identified. Most were detected in positive ion mode, some in negative ion mode, and some in both, such as paeoniflorin and paeoniflorin. The identified compounds include flavonoids, alkaloids, terpenoids, and others classes, among which up to 30 alkaloid compounds are mainly derived from Sophorae flavescentis Radix and Cortex erythrie. Among the top 10 compounds screened by network pharmacology, phaseolin, formononetin, isoxanthohumol, erysodienone, and (-)-estetol were identified. Of these, formononetin and erysodienone had the highest ionic strengths, as shown in Table 3 and Figure 5.

Figure 5.

YGZ223 UPLC-MS/MS total ion flow diagram: (A) positive ion mode (upper: sample; lower: blank control); and (B) negative ion mode (upper: sample; lower: blank control).

Table 3.

UPLC-MS/MS Identification and Analysis of YGZ223 Related Constituents.

Number	Retention time(Min)	Formula	Mol.lon m/z(−)(+)	Quality deviation(ppm)	Main fragment ions	Name	Origin
1	1.05	C₁₃H₁₂N₂O	(+)213.1006	−10.3	170.2820,198.0787,144.0798	Harmine	Cortex erythrie
2	1.09	C₆H₅NO₂	(+)124.0391	−6.4	106.0287,80.0500	Nicotinic acid	Radix Angelicae sinensis
3	1.09	C₁₅H₂₀N₂O₂	(+)261.1591	−4.6	243.1485, 150.1274	9a-Hydroxysophoramine	Radix Sophorae flavescentis
4	1.09	C₁₅H₂₀N₂O₂	(+)261.1591	−4.6	243.1485,136.0624	7a-Hydroxysophoramine	Radix Sophorae flavescentis
5	1.14	C₇H₆O₂	(+)123.0452	4.9	105.0345,77.0399	Benzoic acid	Radix Paeoniae Rubra、Fructus Tribuli
6	1.14	C₇H₆O₂	(+)123.0452	4.9	121.0290,93.0342,65.0387	Salicylaldehyde	Radix Paeoniae Rubra
7	1.17	C₈H₈O₃	(+)153.0548	−2.6	135.0428,107.0488	4-Methoxybenzoic acid	Radix Angelicae sinensis
8	1.21	C₆H₆O₂	(+)111.0443	2.7	81.0343	Hydroquinone	Radix Paeoniae Rubra
9	1.24	C₈H₈O	(+)121.0650	−2.5	107.0488,91.0554	4-Vinylphenol	Radix Angelicae sinensis
10	1.40	C₁₅H₂₀N₂O	(+)245.1660	2.4	148.1110,98.0965	Anagyrine	Radix Sophorae flavescentis
11	1.61	C₁₀H₁₅NO	(+)166.1239	4.2	107.0488,148.1110	Pseudoephedrine OR Ephedrine	Radix Sophorae flavescentis
12	1.71	C₆H₆O₃	(+)127.0401	4.7	259.0537, 107.0509, 97.0293	Pyrogallol	Radix Paeoniae Rubra
13	1.83	C₁₅H₂₄N₂O	(+)249.1968	0.4	231.1887,176.1419,150.1274,148.1135	Matrine	Radix Sophorae flavescentis
14	2.07	C₁₅H₂₂N₂O	(+)247.1821	4.5	179.1554,150.1274,136.1126	Sophocarpine	Radix Sophorae flavescentis
15	2.11	C₁₅H₂₂N₂O	(+)247.1821	4.5	176.1066,148.1110	Lehmannine	Radix Sophorae flavescentis
16	2.14	C₁₅H₂₄N₂O	(+)249.1968	0.4	231.1846,176.1066,150.1274	Allomatrine	Radix Sophorae flavescentis
17	2.62	C₈H₈O₂	(+)137.0595	−5.8	135.0452,107.0488	2′-Hydroxyacetophenone	Radix Paeoniae Rubra
18	2.64	C₇H₆O	(+)107.0488	−8.4	105.0345,77.0399	Benzaldehyde	Radix Paeoniae Rubra、Herba Dendrobii
19	2.69	C₈H₇NO	(+)134.0602	−3.0	104.0491,92.0500	1H-Indol-3-ol	Radix Paeoniae Rubra
20	2.69	C₁₅H₂₂N₂O₂	(+)263.1768	3.0	245.1660,150.1274	Oxysophocarpine	Radix Sophorae flavescentis
21	2.86	C₇H₈O₂	(+)125.0598	−4.0	123.0452,93.0342,91.0554	Salicyl alcohol	Radix Paeoniae Rubra
22	2.92	C₁₅H₂₄N₂O₂	(+)265.1922	2.3	247.1821,205.1325,148.1135	oxymatrine	Radix Sophorae flavescentis
23	2.95	C₁₅H₂₂N₂O₂	(+)263.1768	3.0	168.1395,150.1274	Mamanine	Radix Sophorae flavescentis
24	3.05	C₁₅H₂₀N₂O	(+)245.1660	2.4	136.1126,108.0449	Neosophoramine	Radix Sophorae flavescentis
25	3.54	C₇H₈O	(+)109.0653	−0.9	107.0488,77.0399,79.0554	P-Cresol OR o-Cresol	Radix Angelicae sinensis
26	3.57	C₁₀H₁₂O₅	(−)211.0607	0.5	169.0124,125.0223	Propyl gallate	Radix Paeoniae Rubra
27	3.85	C₁₆H₁₈O₉	(−)353.0881	2.3	191.0561,179.0356,161.0219,135.0446	Neochlorogenic acid	Radix Angelicae sinensis³⁰
28	4.12	C₁₅H₂₀N₂O	(+)245.1660	2.4	217.1340,203.1183,160.0772	Rhombifoline	Radix Sophorae flavescentis
29	4.81	C₇H₆O₃	(+)139.0405	7.2	121.0290,93.0342	Salicylic acid	-
30	5.12	C₁₅H₂₄N₂O₂	(+)265.1922	2.3	150.1274,138.1276,126.0549	Lamprolobine	Radix Sophorae flavescentis
31	5.55	C₁₅H₂₄N₂O₂	(+)265.1922	2.3	247.1821,205.1325,150.1274	Sophoranol	Radix Sophorae flavescentis
32	7.20	C₇H₈O₂	(+)125.0598	−4.0	109.0289,81.0343	Guaiacol	Radix Sophorae flavescentis
33	8.22	C₁₆H₁₈O₉	(−)353.0881	2.3	191.0561,179.0356,161.0219,135.0446	chlorogenic acid	Radix Paeoniae Rubra、Radix Angelicae sinensis³⁰
34	10.55	C₉H₁₀O₃	(+)167.0720	7.2	151.0389,137.0595,123.0452	Paeonol	Radix Paeoniae Rubra
35	10.76	C₁₆H₁₈O₉	(−)353.0881	2.3	191.0561,179.0356,161.0219,135.0446	Cryptochlorogenic acid	Radix Angelicae sinensis³⁰
36	11.23	C₁₈H₁₉NO₄	(+)314.1400	2.5	298.1099,280.0973, 238.0861,178.0862,151.0766	Erysodienone	Cortex erythrie
37	11.95	C₈H₈O₃	(+)153.0548	−2.6	151.0389,123.0452	Vanillin	Radix Angelicae sinensis
38	12.78	C₁₁H₈N₂	(+)169.0774	4.7	140.533,115.0559	Norharmane	Fructus Tribuli
39	13.35	C₁₈H₂₁NO₃	(+)300.1589	−3.7	178.0862, 137.0595,107.0488	Erysodine	Cortex erythrie
40	14.17 14.21	C₂₃H₂₈O₁₁	(−)479.1531 (+)481.1714	−4.6 0.8	525.1597,435.1653,357.1165,283.0803 319.1172,197.0807,161.0599	albiflorin³¹	Radix Paeoniae Rubra
41	14.21	C₈H₈O	(+)121.0650	−2.5	105.0345,73.0399	Acetophenone	Radix Angelicae sinensis
42	14.24	C₉H₁₀O₂	(+)151.0766	4.6	149.0588,107.0488,135.0809	2'-Hydroxy-5'-methylacetophenone	Radix Angelicae sinensis
43	14.24	C₁₇H₁₆O₅	(+)301.1062	−4.6	245.0443,231.0291	Cnidilin	Radix Angelicae sinensis
44	14.59	C₂₀H₂₅NO₄	(+)344.1872	−2.9	297.1144,285.1159,265.0865	Erybidine	Cortex erythrie
45	14.67	C₂₀H₂₄NO₄⁺	(+)342.1707	0.6	297.1144,265.0856,237.0926,191.	Magnoflorine	Radix Sophorae flavescentis
46	16.42	C₁₂H₁₀N₂	(+)183.0933	6.0	168.0653,115.0559	Harman	Fructus Tribuli
47	16.60	C₉H₁₀O₂	(+)151.0766	4.6	137.0595,135.0428,107.0488	2-Methoxy-4-vinylphenol	Radix Paeoniae Rubra
48	16.60 16.66	C₂₃H₂₈O₁₁ C₂₃H₂₈O₁₁	(−)479.1531 (+)481.1714	−4.6 0.8	525.1507,449.1412,327.1049, 121.0274 503.1496,319.1172,179.0705	Paeoniflorin³¹	Radix Paeoniae Rubra
49	16.66	C₈H₁₀O	(+)123.0815	4.1	121.0650,107.0488, 77.0399	2,3-Dimethylphenol	Radix Angelicae sinensis
50	16.66	C₈H₁₀O	(+)123.0815	4.1	107.0488, 93.0342	3-Ethylphenol OR 4-Ethylphenol	Radix Angelicae sinensis
51	16.66	C₉H₁₀O	(+)135.0809	−0.7	133.0647,105.0701	4-Ethylbenzaldehyde	Radix Angelicae sinensis
52	16.69	C₁₀H₈O₄	(+)193.0513	6.2	178.0261,150.0296,133.0269	Scopoletin	Radix Angelicae sinensis
53	17.54	C₁₀H₁₀O₄	(+)195.0665	4.1	177.0555,149.0613	cis-Ferulic acid OR Ferulic acid	Zaocys、Radix Angelicae sinensis³⁰、Radix Paeoniae Rubra³¹
54	18.12	C₁₉H₂₃NO₃	(+)314.1763	2.2	269.1185,237.0926,178.0862,151.0766	Erysotrine	Cortex erythrie
55	18.12	C₁₉H₂₄NO₃⁺	(+)314.1763	2.2	269.1185,237.0926,175.0762,137.0595	Lotusine	Fructus Tribuli
56	18.25	C₁₀H₁₂O₄	(+)197.0807	−3.6	179.0705,151.0766,137.0595	Dihydro-ferulic acid	Zaocys
57	19.92	C₂₀H₂₁NO₅	(+)356.1523	7.0	338.1403,275.0723,206.0831,188.0716	Hunnemannine³²	-
58	20.14	C₁₀H₆O₂	(+)159.0459	8.2	131.0495,105.0324,103.0538	1,4-Naphthoquinone	Radix Angelicae sinensis
59	20.26	C₁₀H₁₀O₄	(+)195.0665	4.1	163.0395, 135.0446	Dimethyl phthalate	Radix Angelicae sinensis
60	21.31	C₂₈H₃₈O₁₃	(−)581.2252	3.1	627.2318,419.1687,401.1593,371.1118,233.0822	lyoniresinol glucoside	-
61	23.21	C₂₁H₂₀O₆	(+)369.1351	3.5	163.0761,147.0446,137.0595,151.0766,121.0290	Suchilactone	Radix Angelicae sinensis
62	23.68	C₂₁H₂₂O₅	(+)355.1529	−4.5	339.1230,311.1299,285.0763	Isoxanthohumol	Radix Sophorae flavescentis
63	23.74	C₂₁H₂₃NO₅	(+)370.1568	−1.6	290.0954,206.0831,188.0716	Cryptopine³³	-
64	23.74	C₁₀H₁₂O₂	(+)165.0916	0	124.0528,133.0647,149.0613,137.0595	Eugenol OR Isoeugenol	Radix Paeoniae Rubra
65	23.68	C₁₁H₁₂O₃	(+)193.0854	−5.7	161.0599,151.0389,123.0452,162.0690	Myristicin	Radix Angelicae sinensis
66	23.80	C₁₉H₂₁NO₃	(+)312.1594	−1.9	294.1487,269.1185,241.1235,195.0808	(+)-Pronuciferine	Fructus Tribuli
67	26.27	C₁₀H₁₀O	(+)147.0818	5.4	145.0648,121.0650,131.0870	4,7-Dimethylbenzofuran	Radix Paeoniae Rubra
68	27.28	C₁₂H₁₄O₃	(+)207.1007	−6.8	189.0916,161.0963,149.0238	2-Pentanoylbenzoic acid	Radix Angelicae sinensis
69	37.37	C₁₆H₁₆O₄	(+)273.1143	5.9	149.0588;131.0495;123.0452	(−)-Vestitol	Cortex erythrie
70	28.61	C₂₀H₁₈O₄	(+)323.1285	0.6	281.0810,263.0708,239.0722	Phaseolin	Cortex erythrie,Radix Sophorae flavescentis
71	29.17	C₁₅H₁₀O₄	(−)253.0497	−1.6	223.0390,208.0520,195.0448	Daidzein	Cortex erythrie
72	28.40	C₁₉H₁₈O₅	(+)327.1242	3.1	295.0969,297.1109,311.0938,219.0649	Eucalyptin	Radix Angelicae sinensis
73	28.40	C₂₀H₁₈O₅	(+)339.1230	−0.6	309.1120,297.0763	Glyceollin	Radix Sophorae flavescentis
74	28.45	C₂₁H₂₃NO₅	(+)370.1568	−1.6	290.0954,206.0831,188.0716	Allocryptopine³²	-
75	29.42	C₁₂H₁₄O₃	(+)207.1007	−6.8	177.0555,161.0599,133.0647,	Ethyl p-methoxycinnamate	Radix Angelicae sinensis
76	29.88	C₂₈H₃₄O₁₅	(−)609.1838	3.1	301.0690,286.0475,242.0578	Hesperidoside	-
77	30.38	C₁₄H₁₂O₂	(+)213.0916	0	105.0345, 91.0554	Benzyl benzoate	Radix Paeoniae Rubra
78	30.38	C₂₇H₃₀O₁₃	(+)563.1763 (−)561.1613	−0.4 0.9	585.1553,269.0816 607.1693, 267.0626	Kushenol O	Radix Sophorae flavescentis
79	30.38	C₁₆H₁₂O₄	(+)269.0816	0.7	254.0590,237.0598,213.0916,197.0602	Formononetin	Radix Sophorae flavescentis、Cortex erythrie
80	32.59	C₁₇H₁₈O₄	(+)287.1268	−5.2	573.2488,193.0882,135.0446,121.0290	Loureirin A	Fructus Tribuli
81	32.64	C₁₇H₁₈O₄	(+)287.1268	−5.2	163.0395,123.0452	Isosativan	Fructus Tribuli
82	35.07	C₁₅H₁₂O₄	(+)257.0815	0.4	239.0690,211.0713,137.0260	Isoliquiritigenin	Cortex erythrie
83	35.12	C₁₆H₁₂O₅	(+)285.0779	5.6	255.0645,175.0383,151.0389	Maackiain	Radix Sophorae flavescentis
84	35.16	C₁₂H₁₂O₂	(+)189.0916	0.5	153.0700,171.0788,145.1009	3-Butylidenephthalide	Radix Angelicae sinensis
85	36.15	C₁₂H₁₄O₄	(−)221.0800	−6.3	177.0902,121.0274	Senkyunolide D	Radix Angelicae sinensis
86	36.62	C₁₄H₁₄O₂	(+)215.1066	−2.8	137.0595,123.0452,91.0554,77.0399	Dihydropinosylvin	Radix Angelicae sinensis
87	37.14	C₂₇H₄₂O₄	(+)431.3173	2.8	593.3707,413.3086,395.2933,299.2379,281.2285	hecogenin	Fructus Tribuli
88	39.63	C₁₄H₂₂O	(+)207.1749	−2.4	177.1644,121.1010	2,4-Di-tert-butylphenol	Radix Paeoniae Rubra
89	48.66	C₁₂H₁₄O₂	(+)191.1059	−6.8	173.0973,145.1009,129.0684,128.0615,115.0559	Ligustilide OR cis-Ligustilide	Radix Angelicae sinensis
90	48.69	C₂₄H₂₈O₄	(+)381.2069	0.8	251.1062,191.1059,173.0973	Angelicide	Radix Angelicae sinensis
91	48.69	C₂₄H₂₈O₄	(+)381.2069	0.8	191.1059,173.0973,149.023	Levistilide A	Radix Angelicae sinensis

Fragmentation and Structural Analysis of Main Constituents

Compounds 13, 14, 16, and 24 are alkaloids with the same skeleton. Regarding compound 13, with a retention time of 1.83 min, the first-order mass spectrometry excimer ion peak is 249.1968 [M + H]⁺, and the chemical formula is C₁₅H₂₄N₂O. In the positive ion mode, the second-order mass spectrometry fragment ions include m/z 231.1887, 176.1419, 150.1274, and 148.1135. The fragmentation pattern is shown in Figure 6A, which is consistent with the reported reference,³⁴ and it is speculated that the compound is matrine. Compounds 14, 16, and 24 are alkaloids of the same skeleton as matrine, and the corresponding secondary mass spectrometry fragment ions are shown in Table 3. Compound 23 is an oxidized derivative of compound 13, with the chemical formula C₁₅H₂₄N₂O₂. The first-order mass spectrometry quasi-molecular ion peak is 265.1922 [M + H]⁺, and the second-order fragment ions are m/z 247.1821, 205.1325, and 148.1135. Compared with the reference substance and literature data,³⁴ 23 is speculated to be oxymatrine. Compound 20 is an oxidized derivative of compound 14, whose fragmentation pattern is shown in Figure 6B and molecular and fragment ions are shown in Table 3.

Figure 6.

Pyrolysis mechanisms in positive ion mode for: (A) matrine; (B) oxymatrine; and (C) formononetin.

Compound 79 has a retention time of 30.38 min, with a first-order excimer ion peak of 268.0816 [M + H]⁺ and a chemical formula of C₁₆H₁₂O₄. The main second-order fragment ions are m/z 254.0590, 253.0522, 237.0598, 213.0916, and 197.0602, and the fragmentation pattern is shown in Figure 6C. Based on the database and reference substance data, it is speculated that compound 79 is formononetin,³⁵ which is isolated from the Cortex Erythrinae and Sophorae Flavescentis Radix.

Compound 40 has a retention time of 14.21 min. In the positive ion mode, the first-order excimer ion peak is m/z 481.1714 [M + H]⁺, while the second-order mass spectrometry fragment ion peaks are m/z 359.1357, 319.1172, 197.0807, 161.0599, and 135.0809. In the negative ion mode, the secondary fragment ions include m/z 525.1597, 435.1653, 357.1165, and 283.0803. It is speculated that compound 40 is albiflorin, while fragment ion m/z 319.1172 is the peony lactone aglycone ion resulting from glucose loss. The fragmentation pattern is shown in Figure 7.

Figure 7.

Fragmentation mechanism of albiflorin in positive ion mode.

Compound 87 has a retention time of 37.14 min. In the positive ion mode, a quasi-molecular ion peak of m/z 593.3707 [M + H]⁺ was detected via first-order mass spectrometry. Additionally, a m/z 431.3173 [M + H]⁺ ion peak was identified, differing 162 Da from the quasi molecular ion peak, indicating a sugar molecule in the parent molecule. The secondary fragment ions in positive ion mode include m/z 413.3086, 395.2933, 299.2379, and 281.2285. Compound 87 is speculated to be hecogenin, and the fragmentation pattern is shown in Figure 8.

Figure 8.

Fragmentation mechanism of hecogenin in positive ion mode.

Molecular Docking Result

To determine the viability of chemical constituent binding to target proteins, AutoDock Vina software was used to screen the top 5 proteins from the network pharmacology, and to dock the top 2 ion strength compounds detected by UPLC-MS. Of the proteins, PI3 K is a complex, so the 3 subunits PIK3CA, PIK3CB, and PIK3CD were docked separately. The binding energies of the 5 proteins with the 2 compounds are all less than −5.0 Kcal· mol⁻¹, indicating good binding ability (Table 4). PyMOL software was then used to visualize the docking results, some of which are shown in Figure 9. Formononetin has the lowest binding energy with AKT1, indicating the strongest binding force. The receptor ligand interaction site is located at amino acid residues ILE-290 and THR-211, which are hydrogen bonded. The region where these 2 residues are located may be the key region of action.

Figure 9.

Molecular docking diagrams of formononetin and erysodienone with related targets (binding energy below −7 Kcal· mol⁻¹): (A) formononetin and EGFR; (B) formononetin and AKT1; (C) formononetin and GSK3β; (D) formononetin and mTOR; (E) erysodienone and AKT1; and (F) erysodienone and GSK3β.

Table 4.

Docking Binding Energies of Formononetin and Erysodienone With Various Targets.

Molecular docking result	Binding energy (Kcal•mol⁻¹)
Molecular docking result	Formononetin	Erysodienone
EGFR (PDBID: 7SYE)³⁶	−8.1	−6.4
AKT1 (PDBID: 3O96)³⁷	−9.8	−7.3
mTOR (PDBID: 7TZO)³⁸	−7.6	−7.4
GSK3B (PDBID: 1PYX)³⁹	−7.8	−7.1
PIK3CD (PDBID: 7LQ1)⁴⁰	−7.9	−6.9
PIK3CA (PDBID: 2RD0)⁴¹	−7.7	−7.1
PIK3CB (AF-P42338-F1)	−7.7	−6.7

Molecular Dynamics Simulation Results

The RMSD results show that the overall fluctuations between 0-20 and 50-80 ns are relatively small and stable (Figure 10A). The fluctuations between 20 and 50 ns are caused by conformational adjustments of small molecules in the pocket, which did not escape the protein during this period, remaining bound. The overall RMSF of the protein is at a relatively low level (Figure 10B). The N- and C-termini of the protein are less restricted by other peptide segments and have greater flexibility, resulting in significant fluctuations at both ends in the figure. The RMSF values around Res100-150 are relatively high since this peptide segment belongs to a random curled secondary structure with greater flexibility caused by bending under the influence of the surrounding environment. However, it is distant from the small molecule binding region, so it will not have a significant impact on the docking. Radius of gyration (Rg) characterizes protein structure compactness and changes in the degree of peptide chain looseness during the simulation process. The Rg value fluctuated to some extent during the first 10 ns of simulation, showing an overall downward trend. After 10 ns, the Rg value decreased to around 2.5 nm, remaining vibrationally stable throughout the following 70 ns, with reduced fluctuations. Hence, the protein can be considered to remain stable during this period (Figure 10C). The HBond results showed that during the 0 to80 ns period, a certain number of hydrogen bonds were maintained between small molecules and proteins, and there was no absence of hydrogen bonds or detachment from protein binding cavities, indicating relatively stable binding (Figure 10D).

Figure 10.

Molecular dynamics simulation of various analysis indicators: (A) RMSD; (B) RMSF; (C) Rg; and (D) Hbond.

After periodic elimination of the simulated trajectory, the conformations of the formononetin-AKT1 complex at 0 and 80 ns were extracted and compared for overlap. In Figure 11A, the green part represents the initial structure at 0 ns, while the blue part represents the simulated final structure at 80 ns. Comparison of the 2 shows that the flexible side chains of the protein undergo distorted conformational changes after simulation. At the same time, there are also changes in the conformation and position of the small molecules. Based on the analysis of RMSD and Rg, it can be concluded that the 80 ns composite is relatively stable. Hence, the interaction force was analyzed between small molecules and the proteins at 80 ns. Formononetin formed salt bridge interactions with residues Asp292, Thr291, and Met281, and hydrogen bond and thiol residue Π-bond interactions. The binding free energy (MM/GBSA) analysis of the trajectory of the formononetin-AKT1 complex during the 50 to 80 ns period showed an overall binding energy of −20.65 kcal/mol, indicating a strong tendency for small molecules to bind to the proteins with a stable binding. Based on MM/GBSA, the key amino acids that interact with the small molecules during the simulation process were analyzed. Among these, Lys158, Gly159, Val164, Lys179, Lys276, Glu278, Asn279, Asp292, Thr312, and Tyr315 are key amino acids that mainly interact with the small molecules during the stable 50 to 80 ns period (Figure 11B).

Figure 11.

Structure diagram of (A) 0 ns (green) and 80 ns (blue) composite; and (B) energy of each residue at 80 ns.

YGZ223 Pharmacodynamic Test Results

No abnormalities were observed in any mice during the experiment, the weight of each group of animals showed a stable growth trend, and no abnormal weight phenomena were observed. During monitoring of the pruritus response, the number of licks in the Model control group after injection of 4-AP significantly increased (P < .01) compared with the blank Control group. Compared with the Model group, the DF group and YGZ223 group significantly reduced the number of 4-AP-induced licks (P < .05), while the other groups of mice showed no statistical difference (P > .05). Compared to the Model control, YGZ223 and DF groups showed a significant decrease in scratching frequency (P < .05), while there was no significant difference between the XFZY group and the Model control group. The results are shown in Table 5 and Figure 12. The efficacy of YGZ223 is somewhat superior to that of DF, yet the two are not significantly different.

Figure 12.

Number of tickles induced by 4-AP in each group of mice: * P < .05, ## P < .01.

Table 5.

Number of Tickles Results in Mouse Tickles Test (n = 8; unit: times; X ± SD).

Group	D₇
Control	17.0 ± 11.8
Model	59.9 ± 22.6^##
XiaoFengZhiYang	59.6 ± 18.6
Diphenhydramine	43.1 ± 23.4*
YGZ223	33.8 ± 19.9*

Significantly different from the blank control (P ＜.01).

Significantly different from the model comparison (P ＜.05).

Discussion

A total of 91 compounds were identified in YGZ223 using UPLC-MS/MS. The majority of these were alkaloids, such as matrine found in Sophorae Flavescentis Radix, erythridine in Cortex erythrie, and alkaloids lotusine, and harmine. While flavonoids, terpenoids, and phenylpropanoids were also present, they were relatively uncommon. The specific constituents of Radix Paeoniae Rubra, namely paeoniflorin and albiflorin, showed a high level of ion strength. Matrine, sophocarpine, and oxymatrine possess various pharmacological activities such as antibacterial, antiviral, anti-tumor, and protective effects on internal organs and blood vessels.⁴² Erysodine is a competitive antagonist of neuronal nicotinic acetylcholine receptors,⁴³ and it exhibits a DPPH free radical scavenging effect.⁴⁴ Furthermore, flavonoids exhibit anti-inflammatory, liver protective, antioxidant, and antibacterial effects associated with skin pruritus.⁴⁵

Data mining revealed that, among the top 10 active compounds, formononetin and erysodienone had high ionic strength in the UPLC-MS assay, indicating that their content is not low and that they may be key constituents for exerting drug efficacy. Among the intersection targets obtained through screening, 2 potential targets for formononetin appeared in the top 20 key targets, namely EGFR and ESR1. The key targets that erysodienone may act on are EGFR, FRC, PTGS2, and mTOR. Further analysis and screening was performed on the top 20 pathways obtained from the KEGG analysis, finding that EGFR and mTOR were involved in the multiple pathways: pancreatic cancer, endocrine resistance, PI3K-AKT signaling pathway et al. Therefore, it is speculated that EGFR and mTOR are key targets for drug efficacy. Among the 10 GO functions, protein autophysiography, identity protein binding, protein kinase activity and negative regulation of apoptotic process are functions shared by the 2 compounds. The endocrine resistance pathway is the pathway of highest score in the KEGG analysis, and the PI3K-AKT signaling pathway also plays a role in endocrine resistance. EGFR acts on PI3 K and further affects the PI3K-AKT pathway, thereby affecting the downstream protein mTOR. The AKT1 with the highest score in the PPI analysis happens to be on this pathway, so EGFR-PI3K-AKT-mTOR may be a key pathway for the action of formononetin and erysodienone.

EGFR is a tyrosine kinase involved in cell proliferation, mitosis, and carcinogenesis.⁴⁶ EGF binds to EGFR and activates it through a series of protein interactions, thereby affecting downstream signaling cascades such as PI3K-AKT.⁴⁷ EGFR is currently the therapeutic target of first-line anti-tumor drugs, which often have significant side effects such as pruritus, rash, and hypertension. Significant thinning of the epidermal stratum corneum has been observed in patients treated with EGFR inhibitors.⁴⁸ EGFR phosphorylation and MAPK activation were inhibited, resulting in a strong inflammatory response,⁴⁹ further inhibiting downstream signals such as the PI3K-AKT pathway and STATs. TGF-α/EGFR signaling defects are associated with skin barrier damage.⁵⁰ Studies have shown that the skin of AKT1/AKT2 knockout mice is semi-transparent, similar to the skin condition of elderly people, and that mTOR activity in AKT1/AKT2 cells is inhibited.⁵¹ A decrease in AKT1 activity has been observed in skin with specific dermatitis,⁵² which can cause itching. GFR1 knockout mice also have the same skin damage condition,⁵³ and IGFR1 can bind to EGFR, activate the downstream PI3K-AKT pathway, and then activate mTOR to maintain the skin condition. Overall, the proteins EGFR, AKT1 and mTOR may play a key role in alleviating senile pruritus. Analysis of the constituent-target-pathway diagram identified GSK3B and PIK3B as the 2 target genes with highest scores. GKS3B encodes the protein GSK3β and PIL3CB encodes the production of p110β, one of the catalytic subunits of PI3 K involved in the regulation of the PI3K-AKT-mTOR pathway. Activation of the PI3K-AKT-mTOR pathway can phosphorylate GSK3β and inhibit its activity,⁵⁴ and studies have shown that GSK3B inhibition plays a critical role in skin wound healing.⁵⁵ Analysis of the effects of these targets provides further evidence that EGFR, PI3 K, GSK3β, AKT1 and mTOR may be the targets for YGZ223 to exert therapeutic effects in SP.

The molecular docking results showed that formononetin had low binding energy with various proteins, the smallest with AKT1, indicating the strongest binding ability with AKT1 and relatively weak binding ability with other targets. Compared with formononetin, erysodienone has significant binding force with various targets, and a better binding with mTOR. According to the docking results, formononetin is a key compound and AKT1 may be a key target.

In-vivo pharmacological tests showed that YGZ223 has a good anti-pruritic effect in the 4-AP-induced mouse pruritus model, and that the effect is superior to the positive control drug.

This study is a preliminary exploratory study, and experimental verification has not yet been conducted on the screened compounds and corresponding targets. Subsequent experimental verification is required. In-vivo experiments have confirmed the effectiveness of YGZ223, but the 4-AP-induced itching model has limitations and is different from SP, which may be related to the complex pathogenesis of SP. Consequently, in the future, we will consider utilizing in-vitro experiments or other more appropriate animal models for the validation of drug efficacy and mechanisms.

Conclusion

This study is based on network pharmacology and explores the possible mechanism of YGZ223 in the treatment of SP. Compounds with the top 10 scores and targets and pathways with the top 20 scores were screened. Formononetin and erysodienone are potentially key compounds, EGFR, PI3 K, AKT1, GSK3β and mTOR may be key targets, and EGFR-PI3K-mTOR may be a key pathway. Molecular docking shows that both compounds have some binding ability to the target, while formononetin and AKT1 may be more critical. In parallel, pharmacological experiments were conducted, indicating that YGZ223 can alleviate 4-AP-induced itching in mice. The above research provides the basis for further development of YGZ223.

Footnotes

Acknowledgments

We are grateful to Professor Liu Bo for his support of this research, and to the other authors for their assistance at various stages of this study.

Author Contributions

Bo Liu and Sa Ling conceived and designed the whole experiment. Xiankui Shu, Ling Ye, and Shiqi Han participated in and completed all experiments. Xiankui Shu, Ling Ye, and Shiqi Han wrote the manuscript. Lu Liang, Hancheng Song, Shuang Xue, and Yilang Zhao proposed modification suggestions. Bo Liu and Sa Ling reviewed and edited this manuscript. All the authors read and approved final version of the manuscript.

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Ethics Approval

This study has been approved and recognized by the Experimental Animal Management and Use Committee (IACUC) of Hubei Tianqin Biotechnology Research Institute Co., Ltd. Animal Ethics Number: IACUC (Approved) - YJY-2022-016.

Statement of Informed Consent

There are no human subjects in this article and informed consent is not applicable.

ORCID iD

Xiankui Shu

References

Valdes-Rodriguez

Stull

Yosipovitch

. Chronic pruritus in the elderly: pathophysiology, diagnosis and management. Drugs Aging. Mar. 2015;32(3):201‐215. doi:https://doi.org/10.1007/s40266-015-0246-0

Ständer

Weisshaar

Mettang

, et al. Clinical classification of itch: a position paper of the International Forum for the Study of Itch. Acta Derm Venereol. 2007;87(4):291‐294. doi:https://doi.org/10.2340/00015555-0305

Zhang

Shi

, et al. Effect of traditional Chinese medicine berberine on type 2 diabetes based on comprehensive metabonomics. Talanta. May 15 2010;81(3):766‐772. doi:https://doi.org/10.1016/j.talanta.2010.01.015

Chen

Sun

. Central circuit mechanisms of itch. Nat Commun. Jun 16 2020;11(1):3052. doi:https://doi.org/10.1038/s41467-020-16859-5

Gunalan

Indradevi

Oudeacoumar

, et al. Pattern of skin diseases in geriatric patients attending tertiary care centre. J Evol Medical Dental Sci. 2017;6(20):1566‐1570. doi:https://doi.org/10.14260/Jemds/2017/344

Valdes-Rodriguez

Mollanazar

González-Muro

, et al. Itch prevalence and characteristics in a Hispanic geriatric population: a comprehensive study using a standardized itch questionnaire. Acta Derm Venereol. Apr 2015;95(4):417‐421. doi:https://doi.org/10.2340/00015555-1968

Yalçin

Tamer

Toy

Oztaş

Hayran

Alli

. The prevalence of skin diseases in the elderly: analysis of 4099 geriatric patients. Int J Dermatol. Jun 2006;45(6):672‐676. doi:https://doi.org/10.1111/j.1365-4632.2005.02607.x

Tejesh

Gil

. The management of chronic pruritus in the elderly. Skin Therapy Lett. 2010;15(8):5‐9.

Yosipovitch

Rosen

Hashimoto

. Itch: from mechanism to (novel) therapeutic approaches. J Allergy Clin Immunol. Nov 2018;142(5):1375‐1390. doi:https://doi.org/10.1016/j.jaci.2018.09.005

10.

Fang

Dong

Liu

, et al. HERB: a high-throughput experiment- and reference-guided database of traditional Chinese medicine. Nucleic Acids Res. Jan 8 2021;49(D1):D1197‐d1206. doi:https://doi.org/10.1093/nar/gkaa1063

11.

Zhang

Yang

, et al. Symmap: an integrative database of traditional Chinese medicine enhanced by symptom mapping. Nucleic Acids Res. Jan 8 2019;47(D1):D1110‐d1117. doi:https://doi.org/10.1093/nar/gky1021

12.

Kim

Chen

Cheng

, et al. Pubchem 2023 update. Nucleic Acids Res. Jan 6 2023;51(D1):D1373‐d1380. doi:https://doi.org/10.1093/nar/gkac956

13.

Daina

Michielin

Zoete

. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. Mar 3 2017;7:42717. doi:https://doi.org/10.1038/srep42717

14.

Daina

Michielin

Zoete

. Swisstargetprediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res. Jul 2 2019;47(W1):W357‐w364. doi:https://doi.org/10.1093/nar/gkz382

15.

Stelzer

Rosen

Plaschkes

, et al. The GeneCards suite: from gene data mining to disease genome sequence analyses. Curr Protoc Bioinformatics. Jun 20 2016;54:1.30.1‐1.30.33. doi:https://doi.org/10.1002/cpbi.5

16.

Wishart

Feunang

Guo

, et al. Drugbank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. Jan 4 2018;46(D1):D1074‐d1082. doi:https://doi.org/10.1093/nar/gkx1037

17.

Zhou

Zhang

Lian

, et al. Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents. Nucleic Acids Res. Jan 7 2022;50(D1):D1398‐d1407. doi:https://doi.org/10.1093/nar/gkab953

18.

Bardou

Mariette

Escudié

Djemiel

Klopp

. Jvenn: an interactive Venn diagram viewer. BMC Bioinformatics. Aug 29 2014;15(1):293. doi:https://doi.org/10.1186/1471-2105-15-293

19.

Szklarczyk

Kirsch

Koutrouli

, et al. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. Jan 6 2023;51(D1):D638‐d646. doi:https://doi.org/10.1093/nar/gkac1000

20.

Shannon

Markiel

Ozier

, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. Nov 2003;13(11):2498‐2504. doi:https://doi.org/10.1101/gr.1239303

21.

Sherman

Hao

Qiu

, et al. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. Jul 5 2022;50(W1):W216‐w221. doi:https://doi.org/10.1093/nar/gkac194

22.

Berman

Westbrook

Feng

, et al. The protein data bank. Nucleic Acids Res. Jan 1 2000;28(1):235‐242. doi:https://doi.org/10.1093/nar/28.1.235

23.

Varadi

Anyango

Deshpande

, et al. Alphafold protein structure database: massively expanding the structural coverage of protein-sequence space with high-accuracy models. Nucleic Acids Res. Jan 7 2022;50(D1):D439‐d444. doi:https://doi.org/10.1093/nar/gkab1061

24.

Mark

Nilsson

. Structure and dynamics of the TIP3P, SPC, and SPC/E water models at 298 K. J Phys Chem A. 2001;105(43):9954‐9960.

25.

Salomon-Ferrer

Case

Walker

. An overview of the Amber biomolecular simulation package. Wiley Interdisciplinary Rev: Comput Mol Sci. 2013;3(2):198‐210.

26.

Genheden

Ryde

. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opin Drug Discov. May 2015;10(5):449‐461. doi:https://doi.org/10.1517/17460441.2015.1032936

27.

Rastelli

Del Rio

Degliesposti

Sgobba

. Fast and accurate predictions of binding free energies using MM-PBSA and MM-GBSA. J Comput Chem. Mar 2010;31(4):797‐810. doi:https://doi.org/10.1002/jcc.21372

28.

Tingjun

Junmei

Youyong

Wei

. Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations. J Chem Inf Model. 2011;51(1):69‐82.

29.

Nguyen

Roe

Simmerling

. Improved generalized born solvent model parameters for protein simulations. J Chem Theory Comput. Apr 9 2013;9(4):2020‐2034. doi:https://doi.org/10.1021/ct3010485

30.

Tian

Sun

Chi

, et al. Affinity ultrafiltration and UPLC-HR-Orbitrap-MS based screening of neuraminidase inhibitors from Angelica pubescens. J Chromatogr B Analyt Technol Biomed Life Sci. Oct 1 2022;1208:123398. doi:https://doi.org/10.1016/j.jchromb.2022.123398

31.

Chen

Chang

Zhu

. Identification and determination of the major constituents in Traditional Chinese Medicinal formula Danggui-Shaoyao-San by HPLC-DAD-ESI-MS/MS. J Pharm Biomed Anal. Sep 8 2009;50(2):127‐137. doi:https://doi.org/10.1016/j.jpba.2009.03.039

32.

Huang

Chi

Liu

, et al. Profiling and pharmacokinetic studies of alkaloids in rats after oral administration of zanthoxylum nitidum decoction by UPLC-Q-TOF-MS/MS and HPLC-MS/MS. Molecules. Feb 7 2019;24(3):585. doi:https://doi.org/10.3390/molecules24030585

33.

Qing

Cheng

Liu

Zeng

Wang

. Structural speculation and identification of alkaloids in Macleaya cordata fruits by high-performance liquid chromatography/quadrupole-time-of-flight mass spectrometry combined with a screening procedure. Rapid Commun Mass Spectrom. May 15 2014;28(9):1033‐1044. doi:https://doi.org/10.1002/rcm.6874

34.

Huang

Long

Liu

Zhu

. Application of high-performance liquid chromatography coupled with linear ion trap quadrupole orbitrap mass spectrometry for qualitative and quantitative assessment of Shejin-Liyan granule supplements. Molecules. Apr 11 2018;23(4):884. doi:https://doi.org/10.3390/molecules23040884

35.

Gampe

Darcsi

Lohner

Béni

Kursinszki

. Characterization and identification of isoflavonoid glycosides in the root of Spiny restharrow (Ononis spinosa L.) by HPLC-QTOF-MS, HPLC-MS/MS and NMR. J Pharm Biomed Anal. May 10 2016;123:74‐81. doi:https://doi.org/10.1016/j.jpba.2016.01.058

36.

Huang

Ognjenovic

Karandur

, et al. A molecular mechanism for the generation of ligand-dependent differential outputs by the epidermal growth factor receptor. Elife. Nov 30 2021;10:e73218. doi:https://doi.org/10.7554/eLife.73218

37.

Voegtli

Sturgis

Dizon

Vigers

Brandhuber

. Crystal structure of human AKT1 with an allosteric inhibitor reveals a new mode of kinase inhibition. PLoS One. Sep 23 2010;5(9):e12913. doi:https://doi.org/10.1371/journal.pone.0012913

38.

Chen

Takagi

, et al. Interactions between mTORC2 core subunits Rictor and mSin1 dictate selective and context-dependent phosphorylation of substrate kinases SGK1 and Akt. J Biol Chem. Sep 2022;298(9):102288. doi:https://doi.org/10.1016/j.jbc.2022.102288

39.

Bertrand

Thieffine

Vulpetti

, et al. Structural characterization of the GSK-3beta active site using selective and non-selective ATP-mimetic inhibitors. J Mol Biol. Oct 17 2003;333(2):393‐407. doi:https://doi.org/10.1016/j.jmb.2003.08.031

40.

Fradera

Deng

Achab

, et al. Discovery of a new series of PI3K-δ inhibitors from Virtual Screening. Bioorg Med Chem Lett. Jun 15 2021;42:128046. doi:https://doi.org/10.1016/j.bmcl.2021.128046

41.

Huang

Mandelker

Schmidt-Kittler

, et al. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science. Dec 14 2007;318(5857):1744‐1748. doi:https://doi.org/10.1126/science.1150799

42.

Lin

. Matrine exerts pharmacological effects through multiple signaling pathways: a comprehensive review. Drug Des Devel Ther. 2022;16:533‐569. doi:https://doi.org/10.2147/dddt.S349678

43.

Quiroz

Guerra-Díaz

Iturriaga-Vásquez

Rivera-Meza

Quintanilla

Sotomayor-Zárate

. Erysodine, a competitive antagonist at neuronal nicotinic acetylcholine receptors, decreases ethanol consumption in alcohol-preferring UChB rats. Behav Brain Res. Sep 3 2018;349:169‐176. doi:https://doi.org/10.1016/j.bbr.2018.04.038

44.

Tanaka

Etoh

Shimizu

Oh-Uchi

Terada

Tateishi

. Erythrinan alkaloids and isoflavonoids from Erythrina poeppigiana. Planta Med. Dec 2001;67(9):871‐873. doi:https://doi.org/10.1055/s-2001-18852

45.

Machado Dutra

Espitia

PJP

Andrade Batista

. Formononetin: biological effects and uses - A review. Food Chem. Oct 15 2021;359:129975. doi:https://doi.org/10.1016/j.foodchem.2021.129975

46.

Sabbah

Hajjo

Sweidan

. Review on Epidermal Growth Factor Receptor (EGFR) structure, signaling pathways, interactions, and recent updates of EGFR inhibitors. Curr Top Med Chem. 2020;20(10):815‐834. doi:https://doi.org/10.2174/1568026620666200303123102

47.

Runkle

Kharbanda

Stypulkowski

, et al. Inhibition of DHHC20-mediated EGFR palmitoylation creates a dependence on EGFR signaling. Mol Cell. May 5 2016;62(3):385‐396. doi:https://doi.org/10.1016/j.molcel.2016.04.003

48.

Albanell

Rojo

Averbuch

, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol. Jan 1 2002;20(1):110‐124. doi:https://doi.org/10.1200/jco.2002.20.1.110

49.

Xie

Chen

Liu

, et al. Prophylactic effect of nitric oxide donors on rat models of EGFR inhibitor‒induced cutaneous toxicities. J Invest Dermatol. Nov 2022;142(11):3052‐3061.e8. doi:https://doi.org/10.1016/j.jid.2022.04.026

50.

Uribe

Gonzalez

. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy. Pathol Res Pract. Jun 15 2011;207(6):337‐342. doi:https://doi.org/10.1016/j.prp.2011.03.002

51.

Peng

Chen

, et al. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev. Jun 1 2003;17(11):1352‐1365. doi:https://doi.org/10.1101/gad.1089403

52.

Naeem

Tommasi

Cole

, et al. A mechanistic target of rapamycin complex 1/2 (mTORC1)/V-Akt murine thymoma viral oncogene homolog 1 (AKT1)/cathepsin H axis controls filaggrin expression and processing in skin, a novel mechanism for skin barrier disruption in patients with atopic dermatitis. J Allergy Clin Immunol. Apr 2017;139(4):1228‐1241. doi:https://doi.org/10.1016/j.jaci.2016.09.052

53.

Liu

Baker

Perkins

Robertson

Efstratiadis

. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell. Oct 8 1993;75(1):59‐72.

54.

King

Yeomanson

Bryant

. PI3King The lock: targeting the PI3K/Akt/mTOR pathway as a novel therapeutic strategy in neuroblastoma. J Pediatr Hematol Oncol. May 2015;37(4):245‐251. doi:https://doi.org/10.1097/mph.0000000000000329

55.

Jere

Houreld

Abrahamse

. Role of the PI3K/AKT (mTOR and GSK3β) signalling pathway and photobiomodulation in diabetic wound healing. Cytokine Growth Factor Rev. Dec 2019;50:52‐59. doi:https://doi.org/10.1016/j.cytogfr.2019.03.001

Investigation of the Active Ingredients and Mechanism of Action of YGZ223 in the Treatment of Senile Pruritus Using Network Pharmacology and UPLC-MS

Abstract

Keywords

Introduction

Materials and Methods

Materials

Animals

Methods

Chemical Component Acquisition and Target Protein Screening of YGZ223

Prediction of SP Targets and Construction of Protein–Protein Interaction Networks

GO and KEGG Pathway Enrichment Analysis

Constructing “Herb-Ingredient-Target” and “Components-Targets-Pathways” Networks

Preparation of YGZ223 Sample

Chromatography and Mass Spectrometry Conditions

Data Collection, Statistics, and Chemical Composition Identification

Molecular Docking

Molecular Dynamics Simulation of Formononetin-AKT1 complex

Pharmacodynamic Experiment of YGZ223 on 4-Aminopyridine Induced Skin Itching Model in Mice

Result

Obtaining Chemical Components and Targets

PPI Construction and Core Target Screening

Analysis of YGZ223 Effective Constituents Action Target Network Diagram

GO and KEGG Enrichment Analysis of Potential Targets

Constituent-Target-Pathway Network Analysis

UPLC-MS/MS Results

Chemical Composition Analysis of YGZ223

Fragmentation and Structural Analysis of Main Constituents

Molecular Docking Result

Molecular Dynamics Simulation Results

YGZ223 Pharmacodynamic Test Results

Discussion

Conclusion

Footnotes

Acknowledgments

Author Contributions

Declaration of Conflicting Interests

Funding

Ethics Approval

Statement of Informed Consent

ORCID iD

References